

# Memorandum

**To:** Members of the ICOC  
**From:** C. Scott Tocher, Sr. Dir. Board Governance  
**Re:** December 12, 2024  
**Date:** Item 6 - Appointment of Co-Chairs to the Intellectual Property & Industry Subcommittee

---

The mission of the Intellectual Property and Industry Subcommittee is to develop, in consultation with CIRM staff, intellectual property policies and regulations, and to engage industry as a partner in order to advance CIRM's mission and to protect the interests of the State of California in CIRM-funded research. The Subcommittee's jurisdiction includes (1) establishing intellectual property standards that balance the opportunity of the State of California to benefit from the patents, royalties, and licenses that result from basic research, therapy development, and clinical trials with the need to ensure that essential medical research and resulting therapy development are not unreasonably hindered by the standards; (2) overseeing and advising the ICOC with respect to any potential disputes between CIRM and its grantees or partners over intellectual property standards and their application; and (3) while respecting academic freedom, developing and refining policies to encourage industry involvement in CIRM, including among other things, CIRM programs, activities, and funding mechanisms and with CIRM non-industry grantees who are willing to engage with industry.

Established in 2011 by the ICOC, the Intellectual Property and Industry Subcommittee has met 19 times since and was most recently co-chaired by Stephen Juelsgaard and Mohamed Abousalem. Accordingly, pursuant the board's bylaws, the ICOC must appoint the new chair(s) of this subcommittee. It is proposed that the following member be appointed as Co-Chairs of the Intellectual Property and Industry Subcommittee:

- Dr. Hala Madanat
- Dr. Kim Barrett (alternate Dr. Donald Taylor)

Biographical summaries are attached to this memo.

**Requested Action:** It is requested that the Board appoint Drs. Madanat and Barrett (with their respective designated alternates able to substitute) as Co-Chairs of the CIRM Intellectual Property and Industry Subcommittee.

### **Hala Madanat, PhD**

Hala Madanat, PhD, is the Vice President for Research and Innovation at San Diego State University and Albert W. Johnson Distinguished Professor of Public Health. Dr. Madanat stewards the university's expansive research enterprise, leads the development of SDSU's Mission Valley Innovation District, and oversees SDSU's research advancement, research support services and technology transfer efforts, the SDSU Research Foundation, as well as the university's start-up incubator, the Zahn Innovation Platform Launchpad.

Under Dr. Madanat's leadership, SDSU's research reached \$230 million in fiscal 2024 – an almost 65% increase in three years. Dr. Madanat was integral in launching Techstars San Diego Powered by SDSU, a world-class accelerator open to startups from around the world. She led the effort for the first national Academic Health and Human Services Department, a collaboration between SDSU and the County of San Diego Health and Human Services to establish the Live Well Center for Innovation and Leadership to address the need for a diverse workforce pipeline and the health disparities pervasive in the San Diego community today. From 2016 to 2020, Dr. Madanat served as the Director of SDSU's School of Public Health. During her tenure, research funding at the school increased 50 percent and its U.S. News ranking rose to No. 23 nationally.

Dr. Madanat is a distinguished professor of health promotion and behavioral sciences. Her research addresses health disparities through community-engaged research. During the COVID-19 pandemic, Dr. Madanat co-led a \$5.5 million contact tracing program funded by the County of San Diego Health and Human Services Agency aimed at enhancing support in underserved communities and curbing the spread of the novel coronavirus. This provided a platform for additional grants and contracts focused on testing, reopening schools, and vaccine hesitancy.

She serves as the lead principal investigator for the Cancer Research and Education to Advance HealTh Equity (CREATE) funded by the National Cancer Institute. She has led the evaluation of several National Institutes of Health-funded grants and published nearly 100 peer-reviewed publications, book chapters, and books.

### **Kim Barrett, PhD**

Kim Barrett is the Vice Dean for Research and Distinguished Professor of Physiology and Membrane Biology at the University of California, Davis School of Medicine. Barrett is advancing an innovative vision for the future of research at the School of Medicine that emphasizes collaboration to transform health. She is responsible for implementing key initiatives and fostering partnerships across UC Davis Health and with other schools, centers, and colleagues throughout UC Davis. Barrett also leads the medical school's collaborative efforts to develop UC Davis' Aggie Square research program.

Barrett joined UC Davis Health in 2021 with more than 30 years of notable scientific research and institutional leadership experience. Immediately prior to UC Davis, Barrett was a distinguished professor of medicine at UC San Diego and director of the division of graduate

education at the National Science Foundation. She has received numerous honors and awards for her research, teaching, mentoring, and service activities. Barrett is also an internationally recognized scholar in gastrointestinal physiology and has published extensively.

She has received numerous awards for her academic contributions as well as her teaching, administrative skills, and mentoring. These include the 2021 Distinguished Achievement Award for Basic Science from the American Gastroenterological Association.

Barrett is originally from the United Kingdom and earned both her BSc (Medicinal Chemistry, 1979) and her PhD (Biological Chemistry, 1982) from University College, London, England.

### **Donald Taylor, PhD, MBA, CLP (alternate for Kim Barrett)**

Donald Taylor is the inaugural Chief Ventures Officer of UC Davis Health Ventures, where he leads efforts to partner with innovation, entrepreneurship, and industry teams to commercialize human health intellectual property and advance research translation for clinical and financial impact. Before UC Davis, Dr. Taylor was Executive Director of Licensing at Ohio State, where he led a team overseeing licensing and intellectual property for over \$1.3B in annual research across 16 colleges, including the College of Medicine and Wexner Medical Center. Prior to Ohio State, he served as Assistant Vice Chancellor for Commercial Translation in Health Sciences, Executive Director of sciVelo, co-director of the Center for Commercial Applications of Healthcare Data, and Associate Professor of Biomedical Informatics at the University of Pittsburgh from 2016 to 2021. At Pitt, he worked with the health sciences and engineering schools to commercialize health sciences research and intellectual property and also served as Associate Director of Entrepreneurship for the Center for Medical Innovation. He taught courses on medical product entrepreneurship and innovation at Pitt and was a Senior Lecturer at Carnegie Mellon University, where he taught healthcare IT innovation and entrepreneurial methods.

A five-time life sciences entrepreneur, Dr. Taylor previously served as vice president of corporate development at Cellumen, a bio-tools drug discovery company, and its spin-off, Cernostics, a cancer diagnostics company. He was also a global pharmaceutical market segment manager at Thermo Fisher Scientific, leading marketing campaigns for a \$400M portfolio. Before that, he held business development roles at Vivisimo, later acquired by IBM, and co-founded NetHealth, the largest EMR provider for the wound healing market. He has also served on the boards of several biotech companies and spent six years in life sciences economic development and venture investment as an Executive in Residence at the Pittsburgh Life Sciences Greenhouse.

Dr. Taylor's research in breast cancer metastasis and cell therapies has been published in high-impact journals like *Cancer Research*, and he was invited to present at the American Association for Cancer Research. He is a co-inventor on a patent filed from his research in cell therapy within the related field of wound healing.



In 2023, Dr. Taylor was conferred as a distinguished alumnus of the University of Pittsburgh for his pioneering work in biomedical entrepreneurship and research translation. Dr. Taylor earned a BS in information systems from Carnegie Mellon University and his MS, PhD in bioengineering, and MBA from the University of Pittsburgh, where he also completed postdoctoral research in pathology.